Zacks Research Brokers Boost Earnings Estimates for NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Intellia Therapeutics in a report released on Monday, September 8th. Zacks Research analyst Team now expects that the company will earn ($1.16) per share for the quarter, up from their previous forecast of ($1.19). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Intellia Therapeutics’ Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($4.50) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.12) EPS, FY2026 earnings at ($4.59) EPS, Q1 2027 earnings at ($0.89) EPS, Q2 2027 earnings at ($1.04) EPS and FY2027 earnings at ($4.21) EPS.

A number of other analysts also recently issued reports on the company. Canaccord Genuity Group decreased their target price on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating for the company in a research report on Tuesday, June 3rd. Wedbush reissued a “neutral” rating and set a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th. Chardan Capital lowered their price target on Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. HC Wainwright lowered their price target on Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $45.00 price objective (down previously from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Eleven investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $27.11.

Intellia Therapeutics Trading Down 5.0%

Shares of NTLA opened at $11.29 on Wednesday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -2.41 and a beta of 2.28. The stock has a 50 day moving average of $11.59 and a 200 day moving average of $9.61. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $23.76.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company’s quarterly revenue was up 104.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.52) earnings per share.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase acquired 100,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were acquired at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the transaction, the director owned 134,693 shares of the company’s stock, valued at $1,350,970.79. The trade was a 288.24% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Edward J. Dulac III sold 7,462 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the transaction, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. This trade represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,534 shares of company stock worth $153,837 over the last ninety days. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 3.8% in the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock worth $92,508,000 after purchasing an additional 474,629 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock worth $76,447,000 after purchasing an additional 561,978 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Intellia Therapeutics by 5.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company’s stock worth $24,449,000 after purchasing an additional 126,049 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock worth $23,300,000 after purchasing an additional 970,700 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock worth $21,498,000 after purchasing an additional 863,363 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.